Merck Wins FDA Approval for Subcutaneous Keytruda as Exclusivity Challenges Approach on September 22, 2025 Approved Biosimilars checkpoint inhibitors Immunotherapy for cancer Keytruda Keytruda Qlex Merck patent expiration Solid Neoplasm Subcutaneous Injections United States Food and Drug Administration +